Pathological complete response after neoadjuvant chemotherapy plus trastuzumab predicts favourable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study group - Untch, M; Fasching, PA; Ditsch, N (J Clin Oncol, 2011)
et al.